Inverse agonist of PPARγ that promoted osteogenic differentiation of isolated bone marrow-derived mesenchymal stem cells
SR2595 is an inverse agonist of PPARG (PPARγ) with an IC50 value of 30 nM. It was found to promote osteogenic differentiation of isolated bone marrow-derived mesenchymal stem cells accompanied by increased expression of bone morphogenetic proteins BMP2 and BMP6. SR2595 showed good pharmacokinetics and can be administered orally. It caused no significant change in insulin sensitivity, fasting insulin levels, food consumption or body weight when administered orally to mice.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing
Mucoepidermoid carcinoma (MEC) is a life-threatening salivary gland cancer that is driven primarily by a transcriptional coactivator fusion composed of cyclic AMP-regulated transcriptional coactivator 1 (CRTC1) and mastermind-like 2 (MAML2). The mechanisms by which the chimeric CRTC1/MAML2 (C1/M2) oncoprotein rewires
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.